Dr. Masayuki Yazawa's lab focuses on developing new drugs to treat Timothy syndrome and other genetic heart conditions that cause dangerous heart rhythms. The research leverages innovative technologies and human-derived heart cells to create potential therapeutics. Through these efforts, the lab aims to better understand the molecular causes of these disorders and improve treatment options for affected patients.

Dr. Daniel Wacker's research lab explores cellular transporters in the brain that regulate the pH balance, crucial for maintaining proper neuronal function. The lab focuses on understanding the structure and function of specific bicarbonate transporters linked to neurological disorders, aiming to develop tools for drug discovery that could lead to new treatments. By combining various scientific techniques, the lab seeks to uncover the molecular mechanisms behind these transporters and their potential therapeutic applications.

Dr. Lakshmi A. Devi’s lab at the Icahn School of Medicine focuses on understanding how the body's natural opioid system interacts with ketamine, a medication that can treat depression and chronic pain. By studying how ketamine affects opioid receptors and their signaling pathways, the lab aims to uncover the mechanisms behind ketamine's rapid and lasting effects. This research has the potential to lead to better treatments for conditions like opioid use disorder and pain management.

Marta Filizola's research lab focuses on developing safer opioids to combat the opioid crisis by better understanding how different drugs interact with opioid receptors. By combining advanced computational models and experimental imaging techniques, the lab seeks to discover pain-relieving medications that have fewer side effects than traditional opioids. This research is crucial for creating new therapies that can help patients manage pain effectively while minimizing the risks of addiction and overdose.

Dr. Lahouaria Hadri's lab focuses on understanding the genetic and epigenetic factors that contribute to pulmonary arterial hypertension (PAH), a serious and often fatal lung disease. Through research on proteins involved in chromatin remodeling, the lab aims to uncover how these factors alter gene regulation in lung cells, leading to vascular dysfunction. The ultimate goal is to identify potential new therapies targeting these mechanisms to help treat PAH.

Dr. Yi Shi's lab focuses on developing innovative therapies to combat COVID-19 using unique nanobody technologies. The lab aims to create ultrapotent drug candidate cocktails that can neutralize various strains of the SARS-CoV-2 virus. By utilizing advanced proteomics and engineering techniques, the lab is working toward designing cost-effective and effective treatments that can be easily administered, even through inhalation.

Dr. Jian Jin's lab focuses on developing new therapeutic strategies for certain types of cancers and Alzheimer's disease. They specifically research targeted treatments for MLL-rearranged leukemias, multiple myeloma, and Alzheimer's disease by inhibiting key enzymes involved in gene regulation. The lab's innovative work aims to create drug candidates that can be used in clinical trials for patients who currently have limited treatment options.

Dr. Mone Zaidi's lab focuses on exploring the role of pituitary hormones, particularly follicle-stimulating hormone (FSH), in age-related diseases like osteoporosis, obesity, and Alzheimer's disease. They aim to develop therapeutic antibodies that can block FSH to prevent cognitive decline, bone loss, and obesity. The research combines insights from pharmacology, neuroscience, and bone biology to understand how these hormones affect health in older adults and to push new treatments into human clinical trials.

Dr. Ki Ann Goosens leads a research lab focused on understanding how chronic stress affects decision-making processes in the brain. The lab studies the interactions between specific brain circuits and hormones like ghrelin, which play vital roles in determining how we weigh potential risks and rewards. Through innovative approaches such as optogenetics and pharmacological experiments, they aim to uncover the mechanisms that lead to altered decision-making in the context of psychiatric disorders such as depression and PTSD.

Dr. Tony Yuen's lab at the Icahn School of Medicine focuses on understanding how certain hormones affect brain health, particularly in relation to Alzheimer's disease in postmenopausal women. They are developing new tools to target and study the role of a hormone called follicle-stimulating hormone (FSH) in the brain, and how reducing its receptor can help alleviate memory loss and other cognitive issues associated with aging. Their research combines advanced genetic techniques and innovative viral delivery methods to explore potential treatments for these conditions.

Dr. Ming-Ming Zhou's lab focuses on understanding how certain immune cells, specifically a type of T helper cell known as Th2 cells, develop and function in relation to diseases like asthma and allergies. By studying the mechanisms that control gene expression in these cells, the lab aims to uncover new targets for therapies that can better manage and potentially cure allergic diseases.